SCHEMBL2331176

SCHEMBL2331176

COC(=O)CCCCCOc1ccc2nc(-c3ccccc3)n(-c3ccc(OCc4ccccc4)cc3)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 5/20 0.46
PDE3A Q14432 5/20 0.46
P2RY12 Q9H244 4/20 0.46
PDE2A O00408 2/20 0.45
LTB4R Q15722 1/20 0.44
HDAC1 Q13547 4/20 0.44
TOP1 P11387 1/20 0.44
NPC1 O15118 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
KMT2A Q03164 1/20 0.43
RAB9A P51151 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CYP1A2 P05177 2/20 0.42
PDE10A Q9Y233 2/20 0.42
HDAC8 Q9BY41 4/20 0.42
KCNH2 Q12809 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
HDAC3 O15379 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2327572 0.94 MAPT (0.47) PDE3BPDE3AP2RY12PDE2ALTB4R
SCHEMBL4588202 0.92 LTB4R (0.50) PDE3BPDE3AP2RY12PDE2ALTB4R
SCHEMBL2324735 0.92 PDE3B (0.51) PDE3BPDE3AP2RY12PDE2ALTB4R
SCHEMBL2328370 0.92 PDE3B (0.51) PDE3BPDE3AP2RY12PDE2ALTB4R
SCHEMBL4588630 0.92 PDE3B (0.51) PDE3BPDE3AP2RY12PDE2ALTB4R
SCHEMBL2328161 0.91 CYSLTR2 (0.44) PDE3BPDE3AP2RY12PDE2AHDAC1
SCHEMBL2330018 0.91 PDE3B (0.48) PDE3BPDE3AP2RY12PDE2ALTB4R
SCHEMBL2327606 0.91 PDE3B (0.48) PDE3BPDE3AP2RY12PDE2ALTB4R
SCHEMBL2326995 0.91 PDE3B (0.51) PDE3BPDE3AP2RY12PDE2ALTB4R
SCHEMBL2326988 0.89 PDE3B (0.47) PDE3BPDE3AP2RY12PDE2ALTB4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1246808-B1 1,2-DIARYL BENZIMIDAZOLES FOR TREATING ILLNESSES ASSOCIATED WITH A MICROGLIA ACTIVATION BAYER SCHERING PHARMA AG (DE) 2011-08-17 EP disclosed
US-7345075-B2 6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanoic acid isopropyl ester; antiinflammatory agents; microglia activators; neurodegenerative diseases SCHERING AKTIENGESELLSCHAFT (DE) 2008-03-18 US disclosed
US-7329679-B2 1,2 Diarylbenzimidazoles and their pharmaceutical use SCHERING AKTIENGESELLSCHAFT (DE) 2008-02-12 US disclosed
US-7115645-B2 1,2 diarylbenzimidazoles and their pharmaceutical use SCHERING AKTIENGESELLSCHAFT (DE) 2006-10-03 US disclosed
US-20060205803-A1 1,2 Diarylbenzimidazoles and their pharmaceutical use SCHERING AKTIENGESELLSCHAFT (DE) 2006-09-14 US disclosed
US-20060094770-A1 1,2 Diarylbenzimidazoles and their pharmaceutical use SCHERING AKTIENGESELLSCHAFT (DE) 2006-05-04 US disclosed
US-20020006948-A1 1,2 diarylbenzimdazoles and their pharmaceutical use SCHERING AG 2002-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006948-A1 1,2 diarylbenzimdazoles and their pharmaceutical use CYP2E1, CYP1B1, CYP1A1 PDE3B 362/4885PDE3A 483/4885P2RY12 565/4885
US-20060094770-A1 1,2 Diarylbenzimidazoles and their pharmaceutical use ATP6V1B2, IL1B, GMFG PDE3B 319/4885PDE3A 415/4885P2RY12 232/4885
US-20060205803-A1 1,2 Diarylbenzimidazoles and their pharmaceutical use ATP6V1B2, IL1B, GMFG PDE3B 319/4885PDE3A 415/4885P2RY12 232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.